Agendia AI Assay Shows High Concordance With MammaPrint in Breast Cancer Study

• Agendia on Oct. 25, 2026, announced clinical validation of an investigational AI-driven digital pathology assay for breast cancer recurrence risk.
• Results were already presented at the ESMO Congress 2026 in Madrid, showing strong agreement with MammaPrint classifications.
• Validation involved 372 early-stage breast cancer patients in the prospective RASTER study, with median follow-up of 10.3 years.
• Patients classified as low risk had better breast cancer-specific survival; digital risk classification outperformed clinical factors in predicting survival.
• The approach uses routine pathology images to infer genomic risk, potentially expanding access where tissue-based genomic testing is limited.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agendia NV published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.